�ٺ���Ƶ

News from �ٺ���Ƶ Health

Diverse City Leaders And Organizations Join The HealthyNYC Campaign. (Harlem World Magazine (NY))

(NY) (6/11) “New York City Health Commissioner Dr. Ashwin Vasan introduced representatives from more than 15 organizations that have signed on to support the city’s goal” with the HealthyNYC campaign, which “aims to promote longer, healthier lives in New York City.” Organizations include �ٺ���Ƶ Health. Lorna E. Thorpe, PhD, MPH, the Anita Steckler and Joseph Steckler Professor of Population Health, chair, Department of Population Health, vice chair, Strategy and Planning Dept Population Health, said, “�ٺ���Ƶ Health, one of the nation’s premier health systems, is proud to champion HealthyNYC.” Olugbenga G. Ogedegbe, MD, MPH, professor, Department of Population Health, the Dr. Adolph and Margaret Berger Professor of Medicine and Population Health, said, “Through its unwavering dedication to excellence and equity in patient care, �ٺ���Ƶ continues to improve the health and well-being of the communities serve in New York City and beyond.”

Bariatric Surgery Better For Weight Loss Than GLP-1 Drugs Such As Ozempic. (Medical News Today)

(6/11) “‘Diet and exercise do not work for the vast majority of people,’ said Christine J. Ren-Fielding, MD, professor, Department of Surgery, chief, Division of Bariatric Surgery, in New York,” who was not involved in the study.

AI Program Accurately Diagnoses Common Lung Cancer From Tissue Images. (Tech Times)

(6/11) “In a recent study published in Nature Communications, researchers from �ٺ���Ƶ Health’s Perlmutter Cancer Center and the University of Glasgow have developed a cutting-edge AI program capable of accurately diagnosing adenocarcinoma, the most common form of lung cancer,” with study co-senior investigator Aristotelis Tsirigos, PhD, professor, Departments of Medicine, Division of Precision Medicine, and Pathology, saying, “Our computer program can now analyze lung tissue samples in minutes to provide fairly accurate predictions of whether a patient’s cancer will return, predictions that exceed the current standard of care for making a prognosis in lung adenocarcinoma.”

US Has First Case Of Sexually Transmitted Ringworm. (Atlanta Journal-Constitution)

The (6/11) “A rare fungus recently caused the first-ever US case of sexually transmitted ringworm” as reported in a “study helmed by doctors from �ٺ���Ƶ Health” although, according to, Avrom S. Caplan, MD, assistant professor, the Ronald O. Perelman Department of Dermatology, “the new case is nothing for the public at large to fret over.”

Nurse Case Management Boosts Benefit Of Home BP Telemonitoring. (Drug Information Online)

(6/11) “Among predominantly low-income Black and Hispanic stroke survivors with uncontrolled hypertension, the addition of nurse case management to home blood pressure telemonitoring (HBPTM) leads to greater systolic blood pressure reduction than HBPTM alone, according to a study” conducted by Olugbenga G. Ogedegbe, MD, MPH, professor, Department of Population Health, the Dr. Adolph and Margaret Berger Professor of Medicine and Population Health and colleagues.

Also reporting is (6/11).

How The Body Roundness Index May Replace The Body Mass Index. (NBC News Now)

(6/11) Natalie E. Azar, MD, clinical associate professor, Department of Medicine, Division of Rheumatology, “explains scrutiny over BMI and how” a newly published “alternative to the body mass index measurement called the body roundness index” may “be more precise in estimating weight composition.”

COVID-Flu Combination Vaccine Shows ‘Positive’ Results In Late-Stage Trials, Moderna Says. (Chronicle Live)

(6/10) “Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine and Clinical Innovation, and a Fox News medical contributor, was also not involved in the trial but shared insights,” saying that “The phase 3 clinical trials look excellent – safe and effective, with more antibodies made against both than when either immunization is given alone.”

Experimental Alzheimer’s Drug Gets FDA Advisory Panel’s Thumbs-Up: ‘Progress Is Happening’. (Fox News)

(6/11) “Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine and Clinical Innovation, and a Fox News medical contributor, who was not involved in the drug trials, noted that donanemab is very similar to Leqembi, the current drug on the market that blocks amyloid formation.”